Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Enanta Pharmaceuticals (ENTA) Net Margin: 2012-2025

Historic Net Margin for Enanta Pharmaceuticals (ENTA) over the last 14 years, with Sep 2025 value amounting to -122.90%.

  • Enanta Pharmaceuticals' Net Margin rose 7311.00% to -122.90% in Q3 2025 from the same period last year, while for Sep 2025 it was -125.19%, marking a year-over-year increase of 4610.00%. This contributed to the annual value of -125.19% for FY2025, which is 4610.00% up from last year.
  • As of Q3 2025, Enanta Pharmaceuticals' Net Margin stood at -122.90%, which was down 23.29% from -99.68% recorded in Q2 2025.
  • In the past 5 years, Enanta Pharmaceuticals' Net Margin ranged from a high of -99.68% in Q2 2025 and a low of -211.62% during Q1 2023.
  • Over the past 3 years, Enanta Pharmaceuticals' median Net Margin value was -151.71% (recorded in 2025), while the average stood at -160.27%.
  • Per our database at Business Quant, Enanta Pharmaceuticals' Net Margin crashed by 15,839bps in 2021 and then skyrocketed by 8,070bps in 2024.
  • Enanta Pharmaceuticals' Net Margin (Quarterly) stood at -108.92% in 2021, then crashed by 1,398bps to -122.90% in 2022, then slumped by 6,266bps to -185.56% in 2023, then surged by 5,413bps to -131.43% in 2024, then soared by 7,311bps to -122.90% in 2025.
  • Its last three reported values are -122.90% in Q3 2025, -99.68% for Q2 2025, and -151.71% during Q1 2025.